HealthKey acquired Syndi Health to add personalized clinical assessment technology and broaden its offering.
SourceAI-powered Patient Identification for Clinical Trials
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
HealthKey is an Austin-based healthtech company that uses AI to prescreen EHR data and identify patients eligible for clinical trials, helping research sites increase enrollment and revenue while reducing manual chart review.
Primary product
AI-powered patient identification for clinical trials
Founded
2023
Headquarters
Austin, Texas, United States
Team size
1-10
Work style
Onsite
Industry
Software Development
Sub-industry
AI-powered clinical trial patient identification
Offices
0 jobs at HealthKey
Check back later for new openings
Business model
Stage
pre-seed
Total raised
$500K
Latest round
Pre-Seed · Apr 2025
Latest amount
$500K
Apr 2025 · Y Combinator
Leadership
Cofounder, CEO
CTO
Founding Member
Medical Director
Partner
Investors
Customer-obsessed, high-intensity, high-standard, in-person team that emphasizes craft and fast execution.
Work style
Onsite
Compensation
A current YC-listed founding GTM Account Executive role shows $80K-$100K base, $80K-$100K variable, $160K-$200K OTE, plus equity.
Benefits
Pricing
$0 upfront cost; success fees per patient enrolled/qualified.
Differentiators
Technology
Customers
Competitors
HealthKey acquired Syndi Health to add personalized clinical assessment technology and broaden its offering.
SourceFinSMEs · Jun 2025
Summarizes the acquisition and notes the deal amount was undisclosed.
Tech.eu · Jun 2025
Reports HealthKey's acquisition of Syndi Health, saying the deal strengthens its AI and personalized healthcare offering and brings Syndi's CEO Ben Lakey into HealthKey's operations team.
UKTN · Jun 2025
Says the acquisition was finalized on May 1 and that HealthKey will combine its marketplace capabilities with Syndi Health's clinical assessment technology.
FinSMEs · Apr 2024
Reports HealthKey closed a £1.13M seed round led by Aviva Ventures, with support from Ascension, Oxford Capital, and Cur8 Capital.